ABSTRACT Two distinct benzodiazepine receptors are solubilized differentially by various detergents. The receptor sites that resist solubilization, designated type I, are most highly concentrated in the cerebellum and corpus striatum whereas the more readily solubilized receptors, type II, are most enriched in the hippocampus. The type I receptors display higher affinity for Pcarboline esters and a triazolopyridazine whereas several benzodiazepines do not differentiate the two receptors. The type I receptors can be solubilized with 2% Triton X-100/1 M NaCI; they retain the same drug specificity as in the particulate state.
The diverse effects ofbenzodiazepines may involve distinct subpopulations of benzodiazepine receptors (1, 2) . For instance, CL-218872, a triazolopyridazine, potents at benzodiazepine receptors and displays an antianxiety profile in rats but with minimal sedative effects (3) (4) (5) . Some ,B-carboline derivatives also discriminate -between binding sites in different brain regions in a fashion similar to CL-218872 (6) (7) (8) (9) (10) . Type I receptors were suggested as those most sensitive to the carboline derivatives and CL-218872 and are most concentrated in the cerebellum. Type II receptors have a lesser sensitivity to these drugs. Although regionally varying potencies of CL-218872 suggest receptor heterogeneity, these variations could merely reflect tissue constituents (11) that vary regionally.
One oftwo protein bands labeled in crude brain homogenates by [3H] flun'itrazepam appears to be more sensitive to displacement by CL-218872 (12) ; however, this difference could reflect either two receptor proteins or tissue-induced modifications in mobility of'a single protein. Physical separation ofreceptor subtypes might clarify the pharmacologic heterogeneities. Benzodiazepine receptors have been solubilized from brain membranes (13) (14) (15) (16) and partially purified (17) .
We now report differential solubilization of two benzodiazepine receptor proteins from brain -membranes which show different drug specificities consistent with types I and II benzodiazepine receptors. sulfonyl fluoride/l mM Na EDTA containing 50 jg of bacitracin and 5 Ag of soybean trypsin inhibitor per ml and then centrifuged at 50,000 x g for 15 min. Pellets were extracted in 2 vol of the homogenizing buffer containing 2% (vol/vol) Triton X-100 for 1 hr at 40C and centrifuged at 150,000 x g for 1 hr. The soluble fraction was incubated with concanavalin A-Sepharose (2 ml of soluble extract per ml of packed resin) for 12-15 hr at 40C, washed with 500 ml of 0.05 M Tris citrate, pH 7.1/ 0.1% Triton X-100, and resuspended to be equivalent to 4 ml per g of original tissue. The pellet was extracted a second time with. 2% Triton X-100 followed by resuspension and centrifugation five times in 10 vol of 0.05 M Tris citrate (pH 7.1) and resuspended finally to 40 ml per g of original tissue. Salt extraction was performed by incubating the Triton X-100-insoluble pellet with 2 vol ofthe homogenizing buffer containing 2% Triton X-100 and 1 M NaCl for 1 hr at 4°C and then diluted 1:5 prior to centrifugation at 150,000 x g for 1 hr. Salt-soluble material was treated with concanavalin A-Sepharose as described for the Triton X-100-soluble extract. Membranes were normally prepared by washing brain homogenates 10 times by resuspension and centrifugation in 20 vol of 0.05 M Tris citrate (pH 7. 1).
MATERIALS AND METHODS
Membrane-bound receptor was assayed by exposure to 3H-labeled ligands. for 1 hr at 2°C followed by filtration and washing over Whatman GF/B filters. Soluble receptor. immobilized on concanavalin A-Sepharose was assayed in a manner similar to that for membrane-bound receptor.
RESULTS.
Properties of a Concanavalin Assay for Binding of 3H-Labeled Ligands in Soluble Brain Fractions. To avoid the denaturation or proteolytic damage to receptor that might take place during freezing and thawing procedures used to free benzodiazepine and y-aminobutynic acid (GABA) receptors from endogenous ligands, we adopted a novel lectin-agarose immobilization assay for soluble receptors (18) .
The receptor first was bound to concanavalin A beads which were washed extensively prior to exposure to 3H-labeled ligand. (Fig. 3) brain clearly showed multiphasic binding. Receptors solubilized by Triton X-100 alone showed only a lowaffinity component whereas the residual pellet after Triton X-100 treatment exhibited a single class of high-affinity binding Similarly, the observation that PCC has about 8-25 times greater affinity for the residual membranes after Triton X-100 treatment than for the Triton X-100-soluble fractions supports the idea that the Triton X-100-soluble and -insoluble preparations represent type II and type I receptors, respectively. (Table 4) . When brain membranes previously extracted twice with 2% Triton X-100 were treated again with 1% or 2% Triton X-100, only about 3% of the residual benzodiazepine binding was solubilized. Similarly, treatment of these membranes with 1 M NaCl alone did not solubilize a significant portion ofreceptors. However, treatment of these membranes with 1 M NaCl together with 2% Triton X-100 solubilized about halfofthe Triton X-100-insoluble benzodiazepine receptor content. Similar results were obtained with sodium cholate together with 1 M NaCl or 1 M KSCN. A second treatment of the membranes with 1 M NaCI plus 2% Triton X-100 further solubilized about a third of the benzodiazepine sites that resisted solubilization with the initial salt plus detergent treatment.
Drug specificity experiments indicated that a major portion of the receptor solubilized by salt plus Triton X-100 treatment is of the type I class (Table 5) . Thus, the potencies of Ro22-7497 and CL-218872 in the fraction solubilized by salt plus Triton X-100 are similar to those in the Triton X-100-insoluble fractions. Moreover, [3H]PCC has a higher affinity for the Triton X-100- treated membranes and the salt plus Triton X-100-solubilized fractions than for the receptor solubilized in Triton X-100 alone.
To ensure that the differential effects of Ro22-7497 and CL-218872 on the two receptor preparations do not merely reflect the different treatment of the various fractions, we examined the influence of benzodiazepines that are thought not to differentiate between type I and type II receptors. Diazepam, clonazepam, Ro7-1986/1, and flurazepam all have the same affinities for native membranes, Triton X-100-treated membranes, Triton X-100-solubilized, and salt plus Triton X-100-solubilized fractions (Table 5) . Moreover, the Kd values of [3H]flunitrazepam binding for all these preparations are the same (Table 4. ) DISCUSSION The major finding of the present study is that two types of benzodiazepine receptor can be separated physically. They appear to correspond to the type I and type II benzodiazepine receptors previously hypothesized on the basis ofdifferential drug effects (3) (4) (5) (7) (8) (9) (10) . Evidence that the differentially detergent-solubilized receptors represent distinct receptor proteins includes the following. 3. The differential solubilization patterns vary regionally. The density of Triton-insoluble receptors is greatest in brain areas where benzodiazepine binding has been reported to have the drug specificity of type I receptors, which coincides with our finding that the Triton X-100-insoluble binding sites display type I drug specificity.
4. The differential solubilization properties with their characteristic drug specificities are observed in brains of several species and in various regions of the brain. 5 . The differential drug specificities are observed after the Triton X-100-insoluble receptors are solubilized with salt plus detergent, so the drug selectivity patterns are not merely an artifact ofcomparing membrane-associated and soluble receptors.
It is unclear whether the type I and type II benzodiazepine receptors that we have separated correspond in molecular weight to the two [3H]flunitrazepam binding subunits observed by Sieghart and Karobath (12) . Conceivably, the Triton X-100-insoluble receptors are tightly associated with cell cytoskeletal structures, which are often insoluble in nondenaturing detergents. This suggests different intracellular locations of the two receptors.
Massotti et aL (20) reported that as little as 0.05% Triton X-100 would solubilize up to 50% of benzodiazepine receptor sites. Under our conditions, substantially higher concentrations of detergent were required to obtain comparable degrees of receptor solubilization.
The assay for solubilized benzodiazepine and GABA receptors immobilized on concanavalin A beads may facilitate studies of soluble receptors. The immobilized receptors can be extensively washed to remove tissue constituents which might affect receptor activity. Receptor immobilization provides a partial purification (17) , because only glycoproteins bind to concanavalin A. The concanavalin A assay is more rapid and involves less physical manipulation than do other assays for soluble receptors involving protein precipitation and so might be useful for detecting small ligands of relatively low affinity.
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